RemovedRisk Factors
Many of our key products are manufactured at or distributed from single locations, and the availability of alternate facilities is limited. If operations at one or more of our facilities is suspended due to natural disasters or other events, including, without limitation, those due to climate change, we may not be able to timely manufacture or
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
The proposed separation of our Urology, Acute Care and OEM businesses may not be completed on the terms or timeline currently contemplated, if at all.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
We recently announced the proposed separation of Urology, Acute Care and OEM businesses. We may encounter challenges to executing the proposed separation of our Urology, Acute Care and OEM businesses on the terms and within the timeframe we announced, or at all. The separation will be subject to the satisfaction of a number of customary conditions, including, but not limited to, the final approval from the Company’s Board of Directors, the filing and effectiveness of a registration statement on Form 10, the receipt of a favorable Internal Revenue Service ruling and tax opinion the Company’s tax advisor with respect to the tax-free nature of the separation, the satisfactory completion of financing arrangements and the receipt of any necessary regulatory approvals. The failure to satisfy any of the required conditions could delay the completion of the proposed separation for a significant period of time or prevent it from occurring at all. Additionally, it is complex in nature, and unanticipated developments or changes, including disruptions in general market conditions, changes in law or challenges in executing the separation of the two businesses, may affect our ability to complete the separation on the terms or on the timeline we announced, or at all. The terms and conditions of the required regulatory authorizations and consents that are granted, if any, may also impose requirements, limitations or costs, or place restrictions on the conduct of the independent companies or impact our ability to complete the separation on the terms or timeline we announced, or at all.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
Although we intend for the proposed separation to be tax-free to the Company’s stockholders for U.S. federal income tax purposes, there can be no assurance that the proposed separation will qualify for such treatment. The IRS ruling and opinion described above will be each based upon various factual representations and assumptions, as well as certain undertakings made by the Company and the new independent company. If any of these factual representations or assumptions are, or become, untrue or incomplete in any material respect, an undertaking is not complied with, or the facts upon which the ruling and opinion are based are materially different from the actual facts relating to the separation, reliance on the ruling and opinion may be jeopardized. If the separation was ultimately determined to be taxable for U.S. federal income tax purposes, we would incur a significant tax liability, while the distribution of shares of the new independent company to the Company’s stockholders would become taxable to them for U.S. federal income tax purposes and the new independent company could incur income tax liabilities as well. In addition, even if the separation is tax-free for U.S. federal income tax purposes, the Company and the new independent company may incur state, local, non-U.S. and/or non-income taxes in connection with the separation, including as a result of the incorporation of the OECD’s Pillar Two global minimum tax framework into local country tax laws, which taxes may be significant.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
We will be exposed to new risks as a result of the proposed separation. The proposed separation may not achieve its anticipated benefits, or our costs may exceed our estimates.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
Our businesses will face material challenges in connection with the proposed separation. These challenges include, without limitation, the diversion of management’s attention from ongoing business concerns; appropriately allocating assets and liabilities among the companies to be separated in the proposed separation, particularly given
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RewordedRisk Factors
As of December 31, 2024, 2025, we had outstanding approximately 46.3 44.2 million shares of our common stock, options to purchase 1.4 1.3 million shares of our common stock (of which approximately 1.1 0.9 million were vested as of that date), restricted stock units covering 0.2 million shares of our common stock (which are expected to vest over the next three four years), performance stock units covering a maximum of 111,696 148,807 shares of our common stock (which are expected to vest over the next three years and depend on our performance with regard to specified financial measures and market performance of our common stock compared to designated public companies) and 38 shares of our common stock to be distributed from our deferred compensation plan.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our Further, until the market has fully analyzed the value of our newly focused company, the price of our common stock or the may experience volatility, and our common stock of the new company may not match some holders’ investment strategies or meet the minimum criteria for inclusion in stock market indices or portfolios, which could cause certain investors to sell their shares, which could in turn lead to declines in the trading price of such stock.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
While we have realized some efficiencies from these initiatives, we may not realize the benefits of these or future initiatives to the extent we anticipated. anticipated, particularly with respect to initiatives involving contingencies that are not completely within our control, such as the completion of acquisitions or divestitures.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Furthermore, our issuance of shares upon the exercise of some or all of the outstanding stock options, as well as the vesting of restricted stock units and some or all of the performance stock units will dilute the ownership interests of existing stockholders, and the subsequent sale in the public market of such shares of our common stock could adversely affect prevailing market prices of our common stock.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Failure to submit required information may result in civil monetary penalties for each payment, transfer of value or ownership or investment interests not reported in an annual submission, up to an aggregate of $150,000 per year (and up to an aggregate of $1 million per year for “knowing failures”), as adjusted annually for inflation.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
However, these effects could have an adverse impact on our liquidity, capital resources, operations, business results and those of the third parties on which we rely, and such impact could be material.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
We cannot predict what additional actions may ultimately be taken by the U.S. or other governments with respect to tariffs or trade relations, what products may be subject to such actions (including subject to U.S. export control restrictions), or what actions may be taken by the other countries in retaliation, or the impact, if any, that any policy changes could have on our business.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
In this regard, if, at the expiration or earlier termination of our swap agreements, the U.S. dollar to euro Euro or to Swiss Franc exchange rate has rates have declined by 10% from the rate in effect at the inception of our agreements, we would be required to pay approximately $75 $100 million or $60 million, respectively, to the counterparties in respect of the notional settlement.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, for the years ended December 31, 2024, 2023 2025, 2024 and 2022, 38%, 37% 2023, 41%, 36% and 36%, 35%, respectively, of our net revenues from continuing operations (based on the Teleflex entity generating the sale) were derived from operations outside the U.S.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
As a result, However, even if both of the proposed separation is Strategic Divestitures are completed, it we may not achieve some or all of the anticipated strategic, financial, operational or other benefits in the expected timeframe, or at all, which could adversely impact our business, results of operations or financial condition.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our In addition to the strategic transformation we announced in February 2025, our strategic initiatives include making significant investments designed to achieve revenue growth and to enable us to meet or exceed margin improvement targets.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
We Moreover, we have begun incurred, and will continue to incur incur, significant expenses in connection with the proposed separation. Strategic Divestitures.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Under our cross-currency swap agreements, a meaningful decline in the U.S. dollar to euro certain exchange rate rates could have a material adverse effect on our cash flows.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We have entered into cross-currency swap agreements with several financial institutions to hedge against the effect of variability in the U.S. dollar to euro certain exchange rate. rates.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
In the event of a significant decline in the U.S. dollar to euro certain exchange rate, rates, our payment obligations to the counterparties could have a material adverse effect on our cash flows.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
In February 2025, we announced our intention to undertake a strategic transformation of the organization. In accordance with this strategy, on December 9, 2025, we announced that we entered into definitive agreements to sell our Acute Care and Interventional Urology (also referred to as "IU") businesses to Intersurgical® Ltd and our OEM business to Montagu and Kohlberg (collectively referred to as the "Strategic Divestitures"). The combined total consideration from the Strategic Divestitures is $2.0 billion in cash, consisting of expected proceeds of approximately $1.5 billion for our OEM business and $530 million for our Acute Care and IU businesses. Both transactions, which were approved at the same time by our Board of Directors, remain subject to certain closing adjustments, customary regulatory approvals and other closing conditions and are expected to be completed in the second half of 2026. We expect to receive net after‑tax proceeds of approximately $1.8 billion upon the completion of both sales. We intend to use the net proceeds primarily to return capital to shareholders through share repurchases and pay down debt, enhancing our financial flexibility to support our growth strategy.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
In connection with the Strategic Divestitures, we have negotiated transition services agreements and other arrangements intended to govern ongoing activities between Teleflex and the respective buyers following the closing dates of the transactions, including interim operating model arrangements and manufacturing and supply services. Although the material terms of these agreements have been substantially determined, they remain subject to finalization and execution. We expect to complete and execute these agreements at the close of each transaction.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
The Strategic Divestitures represent a single plan to exit certain product categories that, in aggregate, meet accounting requirements to be classified as discontinued operations and held for sale as of December 31, 2025. Information provided herein is presented on a continuing operations basis to reflect the impact of the Strategic Divestitures, unless otherwise indicated. For additional information regarding the Strategic Divestitures, refer to Note 5 to the consolidated financial statements included in this Annual Report on Form 10-K.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
On January 8, 2026, we announced the departure of our Chairman, President and Chief Executive Officer, Liam J. Kelly, and the appointment of Stuart A. Randle as Interim President and Chief Executive Officer. In connection with Mr. Kelly’s departure as President and Chief Executive Officer, the Board appointed Stephen K. Klasko, M.D., a current independent director who had been serving as our Lead Director, to serve as the independent Chair of the Board.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
On June 30, 2025, the first day of the third fiscal quarter of 2025, we completed the acquisition of the VI business for a net initial cash payment of €704.3 million, or $825.2 million, subject to certain working capital and other customary adjustments. Borrowings under the delayed draw term loan, discussed in Note 11 and within the Liquidity and Capital Resources section below, and our revolving credit facility were utilized to finance the
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
acquisition, inclusive of transaction-related costs and other associated requirements.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
In connection with the acquisition, we also entered into several ancillary agreements with BIOTRONIK SE & Co. KG to help facilitate business continuity and the integration of the business. These agreements primarily relate to transition support and distribution services and have varying durations extending up to 36 months.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
During the third quarter of 2025, we identified additional indicators of a potential impairment related to the Titan SGS asset group due to lower than expected sales growth during the period and a further downward revision to sales forecasts compared to the forecast utilized in our first quarter 2025 impairment analysis. As a result, in connection with the preparation of the financial statements for the third quarter of 2025, we performed a recoverability test and as a result, we determined that the carrying value of the asset group was not fully recoverable. We subsequently recognized an impairment charge of $100.0 million, representing the amount by which the carrying value of the asset group exceeded its estimated fair value, as determined utilizing the income approach. After the recognition of the impairment charge, the remaining carrying value of the intangible assets of the Titan SGS asset group was $25.1 million as of the end of the third quarter of 2025. Despite the downward revision to sales forecasts, we continue to anticipate revenue growth from the Titan SGS asset group in future periods.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
See the "Results of Operations" section below for information on impairment considerations associated with discontinued operations.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
such years. During the third quarter of 2025, we remitted payment to the related regions to settle the years 2015 through 2018. As a result of the modification in the legislation, along with an adjustment to our calculation of the reserves related to years 2019 through 2025, we recognized a $23.7 million decrease in our reserve during the third quarter of 2025. The decrease in our reserve resulted in a corresponding increase to revenue for the year ended December 31, 2025, of which $9.0 million pertains to prior periods within continuing operations. As of December 31, 2025, our reserve related to this matter was $19.4 million.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
The healthcare industry has been, and may continue to be, adversely affected by government-led initiatives intended to reduce healthcare product costs, such as China’s volume-based procurement programs, which have impacted and may further impact our results. These initiatives have also affected, and may continue to affect, the demand for our products.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
We have implemented various measures designed to mitigate the future impacts of these factors impacting our business, which include tariff specific measures such as supply chain optimization strategies, adjustments to chain-of-custody protocols, and increasing the proportion of USMCA-compliant products in our portfolio, in addition to pricing actions. Nevertheless, additional changes to proposed or enacted tariffs, including those resulting from the February 2026 ruling from the U.S. Supreme Court and any related developments that may follow from it, could materially impact our business, including gross margins and cash flows. The ultimate effect of tariffs and trade policy changes on our results of operations and cash flows will depend on several factors, including the timing, scale, scope, and nature of any tariffs or policies implemented, as well as any associated retaliatory measures.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RemovedMD&A
In connection with preparing the financial statements for the year ended December 31, 2024, we performed our annual impairment test for goodwill and determined that the carrying value of the IU reporting unit exceeded its fair value. Consequently, we recognized a non-cash impairment charge of $240 million in the goodwill impairment line in the Consolidated Statements of Income. The charge was primarily driven by updates to our UroLift forecast, done as part of our annual operating plan process, which reflects management's expectations of a prolonged period of subdued revenue growth due to persistent end-market challenges and changes in competitive pressures in the short to mid-term. Moreover, we anticipate that challenges related to a combination of price, mainly within the office site of service, and volume, will likely continue to impact growth rates.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
As of December 31, 2024, goodwill of the IU reporting unit was $403.9 million after the impairment charge. We estimated the fair value of the reporting unit using both the income and the market approaches. The more significant judgments and assumptions in determining the fair value of the IU reporting unit for our 2024 impairment assessments included the revenue growth rates, the projected operating margins and the discount rate. The quantitative assessment utilized a discount rate of 10.75%. A hypothetical 1% increase in our discount rate estimate used to determine the fair value of the estimated future cash flows would result in an additional impairment charge of $95.0 million.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
In 2023, we began the execution of a plan to terminate the Teleflex Incorporated Retirement Income Plan (the “TRIP”), a U.S. defined benefit pension plan. The TRIP is subject to Title IV of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), and, therefore, must be terminated in accordance with the requirements of ERISA and the process governed by the Pension Benefit Guaranty Corporation (the “PBGC”). The termination date of the TRIP was August 1, 2023, which is the date upon which the timing of the requirements for the formal termination process is based. On September 8, 2023, we filed the required notice regarding the TRIP termination with the PBGC. The termination process requires that all TRIP benefits be distributed to participants, beneficiaries and alternate payees or transferred to a group annuity contract or the PBGC. In December of 2023, we made payments to eligible participants, beneficiaries and alternate payees who elected the one-time lump sum distribution option offered in connection with the TRIP termination, resulting in the recognition of a pre-tax settlement charge of $45.2 million.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
In 2024, we purchased a group annuity contract, using TRIP assets, which resulted in the recognition of net pre-tax settlement charges of $132.7 million for the year-ended December 31, 2024. The participants, beneficiaries, and alternate payees whose benefits were transferred to the group annuity contract will each receive from such group annuity contract the full value of their benefit that accrued under the TRIP. The assets in the TRIP Trust exceed the estimated liability for amounts to be transferred to the PBGC for missing participants and beneficiaries (“surplus plan assets”) and as a result, we transferred $43.0 million of the surplus plan assets to a suspense account within the Teleflex 401(k) Savings Plan, a qualified defined contribution plan. These assets are restricted for future use in accordance with our election to use them to fund future employer contributions to participants in the Teleflex 401(k) Savings Plan. The surplus assets contributed to the suspense account remaining as of December 31, 2024 are
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
included within prepaid and other current assets and other assets on the Consolidated Balance Sheet included below within this Annual Report on Form 10-K.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
We anticipate using the new delayed draw term loan along with revolving credit borrowings under the Credit Agreement and cash on hand to finance the VI Business acquisition. For the year ended December 31, 2024, we incurred transaction costs of $11.5 million in connection with the acquisition, which was recognized in selling, general and administrative expenses in the Consolidated Statement of Income. The majority of the transaction costs were recognized in the fourth quarter of 2024.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
On February 27, 2025, we announced our intention to create a new, independently traded public company comprising Urology (consisting of our Interventional Urology and Urology product categories), Acute Care (consisting of our Respiratory product category, the majority of our Anesthesia product category and certain products within our Interventional Access and Surgical product categories) and our OEM businesses. Our Vascular Access product category, most of our products within our Interventional Access and Surgical product categories and the expected acquisition of the VI business will remain with Teleflex. We intend to target the completion of the transaction in the middle of 2026 via a distribution of newly issued shares of the new company to shareholders that is tax-free for U.S. tax purposes. There can be no guarantees that the proposed separation will be completed on the terms and within the timeframe we announced, or at all.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
The healthcare industry has been impacted by shifts in the delivery, or site of service, of healthcare services, staffing shortages at healthcare facilities and government-led initiatives designed to reduce the cost of healthcare products. These factors have impacted and may continue to influence the demand for our products in the future.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
For a discussion of our results of operations comparison for 2023 and 2022, refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed on February 23, 2024. Discussion of our reportable segment results of operations comparison for 2023 and 2022 is included below within this Annual Report on Form 10-K to reflect the changes in our segment presentation, which occurred during the fourth quarter of 2024.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
We expect to achieve annual pre-tax savings of $12 million to $14 million once the plan is fully implemented. The impact of product rationalization efforts will partially offset the annual pre-tax savings generated by the plan.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
A significant number of jurisdictions, including EU member states, have enacted legislation to establish a 15% global minimum tax in accordance with both the established Pillar Two framework and guidance subsequently published by the OECD. We considered and analyzed the enacted tax laws and guidance in the jurisdictions relevant to Teleflex, and there are no material impacts to our tax provision for the year ended December 31, 2024. We will continue to evaluate the potential impact of future proposed legislation, enacted legislation, and updated guidance as it becomes available but do not currently expect a material increase to our effective tax rate as a result of the Pillar Two framework.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
During the second half of 2024, we were notified that a large customer within our OEM product category intended to vertically integrate a component that we previously manufactured on their behalf. Additionally, we have begun to experience delays in orders from certain customers as they increasingly focus on managing inventories. We cannot predict with certainty the timing of customer inventory corrections; however, should the current trend of customers more tightly managing their inventory persist, it may adversely impact future results.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RewordedMD&A
Asia EMEA operating profit for the year ended December 31, 2024 2025 decreased $6.3 $36.3 million, or 5.2%, 71.4%, compared to the prior year, which was primarily attributable to an increase the adverse impact from the amortization of the step-up in sales carrying value of inventory and marketing expenses to support intangible assets recognized in connection with the VI Business acquisition, as well as higher sales, an increase in research operating and development expenses, integration costs of the acquired business and unfavorable fluctuations in foreign currency exchange rates.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Americas net revenues for the year ended December 31, 2023 2025 increased $115.1 $122.3 million, or 6.0%, 10.6%, compared to the prior year, which was primarily attributable to net revenues of $49.0 million generated by the acquired VI Business, a $125.9 $39.0 million increase in sales volumes of existing products, sales of new products, price increases products and, to a lesser extent, net revenues generated by the acquired Palette and Standard Bariatrics businesses, partially offset by an $86.2 million decrease in sales volume of existing products. price increases.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
EMEA net Net revenues for the year ended December 31, 2024 2025 increased $31.8 by $293.2 million, or 5.4%, 17.2%, compared to the prior year, which was primarily attributable due to net revenues of $202.4 million generated by the acquired VI Business, a $25.8 $35.7 million increase in sales volumes of existing products and price increases, partially offset by the unfavorable impact from an increase $24.2 million in our reserves related to the Italian payback measure. sales of new products.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
EMEA net Net revenues for the year ended December 31, 2024 increased $31.8 decreased by $12.9 million, or 5.4%, 0.8%, compared to the prior year, which was primarily attributable due to a $25.8 $75.7 million increase in sales volumes decrease from the 2023 expiration of existing products the manufacturing and price increases, partially offset by supply transition agreement ("MSA") associated with our 2021 Respiratory business divestiture and, to a lesser extent, the unfavorable impact from an increase in our reserves related to the Italian payback measure.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash used in provided by financing activities from continuing operations was $421.9 $611.5 million during 2024, 2025, which primarily consisted of $200.0 $987.0 million in net proceeds from borrowings under our Senior Credit Facility, $300.0 million in repurchases of our common stock under the accelerated share repurchase agreement, a $161.5 million reduction in net borrowings under our Senior Credit Facility and $63.5 $60.3 million in dividend payments. payments, and contingent consideration payments of $15.5 million.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease increase in interest expense for the year ended December 31, 2024, 2025, compared to the prior year was primarily due to a decrease an increase in our the average outstanding debt balance. balance stemming from new borrowings utilized to fund the VI Business acquisition, partially offset by a lower average interest rate resulting from decreases in interest rates associated with our variable interest rate debt instruments.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Americas operating profit for the year ended December 31, 2023 2025 increased $44.1 $42.7 million, or 6.6%, 10.0%, compared to the prior year, which was primarily attributable to an increase in gross profit resulting as a result of higher revenue from higher sales and price increases and a benefit recognized from decreases in our legacy businesses as well as revenues generated by the estimated fair value of our contingent consideration acquired VI Business.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Asia net revenues for the year ended December 31, 2024 2025 increased $16.1 $38.8 million, or 4.7%, 19.2%, compared to the prior year, which was primarily attributable to a $13.0 net revenues of $51.1 million increase in sales volumes of existing products, and revenues generated by the acquisition acquired VI Business, partially offset by price decreases primarily due to the implementation of Palette. volume-based procurement programs in China.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
EMEA net revenues for the year ended December 31, 2024 increased $31.8 $23.3 million, or 5.4%, 7.3%, compared to the prior year, which was primarily attributable to a $25.8 $13.2 million contribution from price increases, an $11.5 million increase in sales volumes of existing products and price increases, partially offset by the unfavorable impact from and, to a lesser extent, an increase in our reserves related to the Italian payback measure. sales of new products.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
The indicators of a potential impairment primarily arose from lower than anticipated expected sales results from of our UroLift Titan SGS product line (“UroLift"), primarily and anticipated continuing reduced demand for bariatric surgery procedures in future periods, driven by the adverse impact growing adoption of persistent end-market challenges within the U.S. office site of service. GLP-1 products.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
For the year ended December 31, 2024, gross margin increased 50 30 basis points, or 0.9%, 0.5%, compared to the prior year period, year, primarily due to the favorable impact of on gross margin attributed to acquired of the 2023 expiration of the MSA associated with our 2021 Respiratory business divestiture, and divested businesses, price increases and the benefits from cost improvement initiatives. increases.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Asia operating profit for the year ended December 31, 2024 decreased $6.3 $18.7 million, or 5.2%, 29.0%, compared to the prior year, which was primarily attributable to an increase a decrease in gross profit resulting from lower sales and marketing expenses unfavorable impact from product mix, in addition to support higher sales, an increase in research and development expenses, and unfavorable fluctuations in foreign currency exchange rates. sales expenses.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesMD&A
Approximately 92% Substantially all of our net revenues come from single-use medical devices.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesMD&A
The acquisition will include adds a broad suite of coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters, which will complement our interventional product portfolio.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new